ATE400647T1 - C-terminale modifikation von polypeptiden - Google Patents

C-terminale modifikation von polypeptiden

Info

Publication number
ATE400647T1
ATE400647T1 AT05774367T AT05774367T ATE400647T1 AT E400647 T1 ATE400647 T1 AT E400647T1 AT 05774367 T AT05774367 T AT 05774367T AT 05774367 T AT05774367 T AT 05774367T AT E400647 T1 ATE400647 T1 AT E400647T1
Authority
AT
Austria
Prior art keywords
polypeptides
trypsin
xaa2
terminal modification
amino acid
Prior art date
Application number
AT05774367T
Other languages
English (en)
Inventor
Eva Hoess
Frank Bordusa
Rupert Herrmann
Hans-Dieter Jakubke
Wilhelm Tischer
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of ATE400647T1 publication Critical patent/ATE400647T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/48Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424Serine endopeptidases (3.4.21)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/48Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424Serine endopeptidases (3.4.21)
    • C12N9/6427Chymotrypsins (3.4.21.1; 3.4.21.2); Trypsin (3.4.21.4)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00Preparation of peptides or proteins
    • C12P21/06Preparation of peptides or proteins produced by the hydrolysis of a peptide bond, e.g. hydrolysate products

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
AT05774367T 2004-08-13 2005-08-12 C-terminale modifikation von polypeptiden ATE400647T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP04019237 2004-08-13

Publications (1)

Publication Number Publication Date
ATE400647T1 true ATE400647T1 (de) 2008-07-15

Family

ID=34926160

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05774367T ATE400647T1 (de) 2004-08-13 2005-08-12 C-terminale modifikation von polypeptiden

Country Status (10)

Country Link
US (2) US20080064079A1 (de)
EP (1) EP1778839B1 (de)
JP (1) JP4538501B2 (de)
CN (1) CN101010425B (de)
AT (1) ATE400647T1 (de)
CA (1) CA2569707C (de)
DE (1) DE602005008071D1 (de)
ES (1) ES2309785T3 (de)
HK (1) HK1110888A1 (de)
WO (1) WO2006015879A1 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102005046113A1 (de) * 2005-09-27 2007-03-29 Sanofi-Aventis Deutschland Gmbh Verfahren zur Amidierung von Polypetiden mit C-terminalen basischen Aminosäuren unter Verwendung spezifischer Endoproteasen
DE102006031962A1 (de) 2006-07-11 2008-01-17 Sanofi-Aventis Deutschland Gmbh Amidiertes Insulin Glargin
DE102006031955A1 (de) 2006-07-11 2008-01-17 Sanofi-Aventis Deutschland Gmbh Verfahren zur Herstellung von Insulinanaloga mit dibasischem B-Kettenende
MX344293B (es) 2008-10-17 2016-12-13 Sanofi Aventis Deutschland Combinacion de una insulina y un agonista de glp-1.
WO2010115866A1 (en) 2009-04-06 2010-10-14 Novo Nordisk A/S Targeted delivery of factor viii proteins to platelets
PT2498802E (pt) 2009-11-13 2015-04-13 Sanofi Aventis Deutschland Composição farmacêutica que compreende um agonista de glp-1, uma insulina e metionina
BR112012011403B8 (pt) 2009-11-13 2021-05-25 Sanofi Aventis Deutschland composição farmacêutica líquida compreendendo um agonista glp-1 e metionina e uso da mesma
JP5749744B2 (ja) 2010-02-11 2015-07-15 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft Igf−iポリ(エチレングリコール)コンジュゲート
RU2546520C2 (ru) 2010-08-30 2015-04-10 Санофи-Авентис Дойчланд Гмбх Применение ave0010 для производства лекарственного средства для лечения сахарного диабета 2 типа
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
US9408893B2 (en) 2011-08-29 2016-08-09 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for use in glycemic control in diabetes type 2 patients
TWI559929B (en) 2011-09-01 2016-12-01 Sanofi Aventis Deutschland Pharmaceutical composition for use in the treatment of a neurodegenerative disease
LT3229828T (lt) 2014-12-12 2023-06-12 Sanofi-Aventis Deutschland Gmbh Insulino glargino/liksisenatido fiksuoto santykio kompozicija
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第2型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第2型糖尿病病患之治療
US10738338B2 (en) 2016-10-18 2020-08-11 The Research Foundation for the State University Method and composition for biocatalytic protein-oligonucleotide conjugation and protein-oligonucleotide conjugate
EP3650541A1 (de) 2018-11-08 2020-05-13 BioPharma Translationsinstitut Dessau Forschungs GmbH Trypsin-mutante zur c- und n-terminalen modifizierung von polypeptiden
JP7360742B2 (ja) * 2018-12-19 2023-10-13 バイオファーマ トランスレーションズインスティテュート デッサウ フォルシュングス ゲーエムベーハー 酵素特性が改善したトリプシン変異体およびその使用ならびに基質の直交二重修飾のための方法
BR112022011291A2 (pt) 2019-12-10 2022-09-06 Sanofi Sa Método para formar um conjugado de uma sulfonamida e um polipeptídeo

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9001705D0 (sv) * 1990-05-11 1990-05-11 Medscand Ab Saett foer diagnostik av virusbaerande tumoerer genom immunoassay
US5580751A (en) * 1990-09-14 1996-12-03 Carlsberg A/S Process for the preparation of C-terminally amidated peptides
AU6171594A (en) 1993-02-04 1994-08-29 Genentech Inc. Serine protease variants having peptide ligase activity
US6187579B1 (en) * 1993-10-28 2001-02-13 Carlsberg A/S Customized proteases
CN1046531C (zh) 1994-07-25 1999-11-17 伯伦格·曼海姆有限公司 有带电连接基的金属配合物、轭合物及其用途和制备方法
US5985627A (en) 1997-02-28 1999-11-16 Carlsberg Laboratory Modified carboxypeptidase
DE10049673A1 (de) * 2000-10-07 2002-04-25 Univ Leipzig Verfahren zur Herstellung von Peptiden, Peptidmimetika und Proteinen
CN1354253A (zh) * 2001-12-24 2002-06-19 南京医科大学 淡色库蚊胰蛋白酶基因

Also Published As

Publication number Publication date
US8927230B2 (en) 2015-01-06
JP4538501B2 (ja) 2010-09-08
US20080064079A1 (en) 2008-03-13
CN101010425B (zh) 2010-05-26
DE602005008071D1 (de) 2008-08-21
CA2569707A1 (en) 2006-02-16
JP2008508871A (ja) 2008-03-27
HK1110888A1 (en) 2008-07-25
CA2569707C (en) 2013-09-24
WO2006015879A1 (en) 2006-02-16
US20130177940A1 (en) 2013-07-11
ES2309785T3 (es) 2008-12-16
CN101010425A (zh) 2007-08-01
EP1778839B1 (de) 2008-07-09
EP1778839A1 (de) 2007-05-02

Similar Documents

Publication Publication Date Title
ATE400647T1 (de) C-terminale modifikation von polypeptiden
FR2831170B1 (fr) Proteines c modifiees activables directement par la thrombine
MY148447A (en) Method for amidating polypeptides with basic aminoacid d-terminals by means of specific endoproteases
NZ597685A (en) Proteins and nucleic acids from meningitis/sepsis-associated escherichia coli
ATE546533T1 (de) Rekombinante expression von proteinen in einer disulfidverbrückten, zweikettigen form
DK1144607T3 (da) Fremgangsmåde til præsentation af (poly)peptider/proteiner på bakteriofage partikler via disulfidbindinger
NO20074374L (no) Fremgangsmate for fremstilling av polypeptidblandinger ved anvendelse av hydrogenolyse
NZ593837A (en) Recombinantly modified plasmin
CA2443365A1 (en) Methods for the recombinant production of antifusogenic peptides
EP2348053A3 (de) Oligopeptid-Liganden
MXPA03000786A (es) Peptidos de promiostatina y metodos de usar los mismos.
NO913427L (no) Gjaer-forarbeidingssystem som omfatter en negativt ladet aminosyre som er tilstoetende til forarbeidingspunktet.
ATE398179T1 (de) Von rna polymerasen abstammende polypeptide und ihre verwendungen
RS52747B (en) THERAPEUTIC ACTIVE ANALYSIS OF ALFA-MSH
ATE477272T1 (de) Verwendung von stefin a als gerüstprotein
EA201170762A1 (ru) Способы отбора устойчивых к протеазе полипептидов
MX2018009216A (es) Metodo para producir un hidrolizado de proteina empleando una tripeptidil peptidasa de aspergillus fumigatus.
ATE548380T1 (de) Mutante des hgf-precursor-proteins und aktivierte form davon
DE60134230D1 (de) Substraten und nachweise zur wirksamkeit von beta-secretase
NZ601647A (en) Variant hhip1 protein and methods and uses thereof
ATE538806T1 (de) Peptide mit spezifischem sitz in herzgefässen und verwandte konjugate und verfahren
ATE485831T1 (de) Behandlung von neurodegeneration
DE602007010969D1 (de) Zytokinderivate
DK1915617T3 (da) Fremgangsmåder og sammensætninger til identifikation af et peptid, der har en intermolekylær interaktion med et interessemål
SG170757A1 (en) Polypeptide having esterase activity and recombinant esterase and use thereof

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1778839

Country of ref document: EP